Sangamo Therapeutics, Inc. (SGMOQ)
0.068
0.00 (0.00%)
USD |
OTCM |
Jul 16, 16:00
Sangamo Therapeutics Debt to Equity Ratio : -1.020 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | -1.020 |
| December 31, 2025 | -1.878 |
| September 30, 2025 | 4.072 |
| June 30, 2025 | 1.197 |
| March 31, 2025 | 5.070 |
| December 31, 2024 | 1.342 |
| September 30, 2024 | 0.7085 |
| June 30, 2024 | 1.228 |
| March 31, 2024 | 0.5435 |
| December 31, 2023 | 0.4597 |
| September 30, 2023 | 0.2592 |
| June 30, 2023 | 0.1557 |
| March 31, 2023 | 0.1123 |
| December 31, 2022 | 0.1461 |
| September 30, 2022 | 0.1284 |
| June 30, 2022 | 0.1305 |
| March 31, 2022 | 0.128 |
| December 31, 2021 | 0.1281 |
| September 30, 2021 | 0.089 |
| June 30, 2021 | 0.0927 |
| March 31, 2021 | 0.09 |
| December 31, 2020 | 0.0845 |
| September 30, 2020 | 0.08 |
| June 30, 2020 | 0.0833 |
| March 31, 2020 | 0.1103 |
| Date | Value |
|---|---|
| December 31, 2019 | 0.1027 |
| September 30, 2019 | 0.104 |
| June 30, 2019 | 0.0989 |
| March 31, 2019 | 0.0445 |
| December 31, 2018 | 0.0755 |
| September 30, 2018 | 0.0709 |
| June 30, 2018 | 0.0675 |
| March 31, 2018 | 0.1395 |
| December 31, 2017 | 0.1317 |
| September 30, 2017 | 0.0207 |
| June 30, 2017 | 0.02 |
| March 31, 2017 | 0.0313 |
| December 31, 2016 | 0.029 |
| September 30, 2016 | 0.0157 |
| June 30, 2016 | 0.0015 |
| March 31, 2016 | 0.0012 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.237 |
| Oncolytics Biotech, Inc. | -0.099 |
| Sarepta Therapeutics, Inc. | 0.6888 |
| Anixa Biosciences, Inc. | 0.0127 |
| Vicapsys Life Sciences, Inc. | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 59.96M |
| Total Liabilities (Quarterly) | 78.92M |
| Shareholders Equity (Quarterly) | -18.96M |
| Current Ratio | 0.6985 |
| Net Debt Paydown Yield | 2.20% |